Business Context and Reporting Period
This Form 8-K is a current report filed by Point Capital, Inc. (not Silo Pharma, Inc.) on July 23, 2015. The filing addresses corporate governance changes under Item 5.02 regarding the departure and appointment of certain officers.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is the compensation arrangement for the newly appointed Chief Financial Officer, which is a monthly fee of $5,000.
Material Changes
- Resignation: Vadim Mats resigned as Chief Financial Officer, effective July 23, 2015.
- Appointment: Adam Wasserman was appointed as Chief Financial Officer, effective July 23, 2015.
- Disagreement Disclosure: The Company stated there were no disagreements regarding operations, policies, or practices related to Mr. Mats' resignation.
Outlook, Risks, and Management Commentary
Mr. Wasserman brings extensive experience as the CEO of CFO Oncall, Inc. since 1999 and currently serves as CFO for multiple other entities including Cleantech Solutions International, Inc., Pen, Inc., and LegacyXChange, Inc. He holds a bachelor of science in accounting and is a member of the American Institute of Certified Public Accountants. The filing notes no familial relationships with other directors or officers and no material interest in transactions since January 1, 2012.
Investor Verification Checklist
- Verify the correct registrant name is Point Capital, Inc., as the input metadata referenced Silo Pharma, Inc.
- Confirm the effective date of the CFO transition (July 23, 2015).
- Review the new CFO's concurrent roles at other companies to assess potential time commitment conflicts.
- Monitor for any future amendments to this report should a disagreement regarding the resignation arise.